Sign In
Section Navigation
Common TitleLATTE-2
Official Title A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of Cabotegravir (GSK1265744) Plus Rilpivirine (TMC278) For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of Cabotegravir (GSK1265744) Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects
Phase Phase IIB
ClinicalTrials.gov NCT02120352
Treatments
Injectable cabotegravir and Rilpivirine

Injectable cabotegravir and Rilpivirine

Tradename:CabenuvaClass:Long-Acting Injectable Regimens
Categories Treatment-NaiveDual Therapy
Funding
IndustryViiV Healthcare
References
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499-1510.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.